Pharmacy World and Science

, Volume 15, Issue 4, pp 165–170 | Cite as

Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid

  • T. B. Vree
  • M. Van den Biggelaar-Martea
  • E. W. J. Van Ewijk-Beneken Kolmer
  • Y. A. Hekster
Case Reports Practice


The aim of this pilot study was to demonstrate the possible inhibitory effect of probenecid on the renal glucuronidation and on the renal clearance of nalidixic acid in a human volunteer. Under acidic urine conditions, hardly any nalidixic acid is excreted unchanged (0.2%). It is excreted as acyl glucuronide (53.4%), 7-hydroxymethylnalidixic acid (10.0%), the latter's acyl glucuronide 30.9%, and 7-carboxynalidixic acid (4.2%). Under probenecid co-medication the renal glucuronidation of nalidixic acid is reduced from 53% to 16%; the renal clearance of both nalidixic acid and 7-hydroxymethylnalidixic acid are reduced (p <0.001); the intrinsict 1/2 of the metabolite 7-hydroxymethylnalidixic acid increased from 0.48 h to 4.24 h. The amount of acyl glucuronidation of 7-hydroxymethylnalidixic acid was not altered. Thein vitro protein binding of both acyl glucuronides was increased, while no effect on the unconjugated compounds was seen. Nalidixic acid had no effect on the maximal renal excretion rate of probenecid acyl glucuronide.


Clearance Drug interactions Glucuronates Kidney Metabolism Nalidixic acid Probenecid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McChesney EW, Froelich EJ, Lesher GY, Grain AVR, Rosi D. Absorption, excretion and metabolism of a new antibacterial agent nalidixic acid. Toxicol Appl Pharmacol 1964;6: 292–309.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferry N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Nalidixic acid kinetics after single and repeated oral doses. Clin Pharmacol Ther 1981;29:695–8.PubMedGoogle Scholar
  3. 3.
    Portmann GA, McChesney EW, Stander H, Moore WE. Pharmacokinetic model for nalidixic acid in man II. Parameters for absorption, metabolism and elimination. J Pharm Sci 1966;55:72–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Männistö PT. Pharmacokinetics of nalidixic acid and oxolinic acid in healthy women. Clin Pharmacol Ther 1976;19:37–46.PubMedGoogle Scholar
  5. 5.
    Graber H, Perényi T, Ludwig E, Arr M. The human biotransformation of nalidixic acid. Int J Clin Pharmacol Biopharm 1976;13:76–82.PubMedGoogle Scholar
  6. 6.
    Vree TB, Beneken Kolmer EWJ. Direct measurement of probenecid and its glucuronide conjugate by means of high performance liquid chromatography in plasma and urine of humans. Pharm Weekbl [Sci] 1992;14(3):83–7.Google Scholar
  7. 7.
    Vree TB, Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. Pharm Weekbl [Sci] 1992;14(5):325–31.Google Scholar
  8. 8.
    Vree TB, Van den Biggelaar-Martea M, Van Ewijk-Beneken Kolmer EWJ, Hekster YA. Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxynalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans. Pharm World Sci 1993;15(3):98–104.PubMedCrossRefGoogle Scholar
  9. 9.
    Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992, 22:155–63.PubMedCrossRefGoogle Scholar
  10. 10.
    SAS User's guide: basics 1982 edition. Cary: SAS Institute, 1982.Google Scholar
  11. 11.
    Vree TB, Van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of naproxen and its metabolite Odesmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient HPLC analysis, J Chromatogr Biomed Appl 1992;578:239–49.CrossRefGoogle Scholar
  12. 12.
    Ferry N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Influence du probénécide sur la pharmacocinétique de l'acide nalidixique. Therapie 1982;37:645–9.PubMedGoogle Scholar
  13. 13.
    Cuisinaud G, Ferry N, Pozet N, Zech PY, Sassard J. Nalidixic acid kinetics in renal insufficiency. Br J Clin Pharmacol 1982; 14:489–93.PubMedGoogle Scholar
  14. 14.
    Barbeau G, Belanger P-M. Pharmacokinetics of nalidixic acid in old and young volunteers. J Clin Pharmacol 1982;22:490–6.PubMedGoogle Scholar
  15. 15.
    Vree TB, Beneken Kolmer EWJ, Martea M, Bosch R, Shimoda M. High-performance liquid chromatography of sulphadimethoxine and its N1-glucuronide, N4-acetyl and N4-acetyl-N1-glucuronide metabolites in human plasma and urine. J Chromatogr Biomed Appl 1990;526:119–28.CrossRefGoogle Scholar
  16. 16.
    Vree TB, Beneken Kolmer EWJ, Martea M, Bosch R, Hekster YA, Shimoda M. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in humans. Pharm Weekbl [Sci] 1990;12:71–5.Google Scholar
  17. 17.
    Vree TB, Beneken Kolmer EWJ, Hekster YA, Shimoda M, Ono M, Miura T. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfa-6-monomethoxine in humans. Drug Metab Dispos 1990;18:852–8.PubMedGoogle Scholar
  18. 18.
    Vree TB, Beneken Kolmer EWJ, Hekster YA. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans. Pharm Weekbl [Sci] 1991;13(5):198–206.Google Scholar

Copyright information

© Periodicals Service Company 1993

Authors and Affiliations

  • T. B. Vree
    • 1
  • M. Van den Biggelaar-Martea
    • 1
  • E. W. J. Van Ewijk-Beneken Kolmer
    • 1
  • Y. A. Hekster
    • 1
  1. 1.Department of Clinical Pharmacy, Sint Radboud HospitalUniversity of NijmegenGA NijmegenThe Netherlands

Personalised recommendations